Bond.az White LogoBond.az Black Logo

Oxford Lane Capital NAV drops, stock dips

Oxford Lane Capital Corp reports Q4 FY2026 results: NAV per share down, stock falls 4.03%. CLO yields decline. Read more on challenges and outlook.

Benjamin Moore
ByBenjamin Moore- Senior Editor
|
0

Oxford Lane Capital Corp (OXLC) reported weak Q4 FY2026 results. Net asset value (NAV) per share fell to $10.56 from $15.51 in the previous quarter, driven by unrealized depreciation and realized losses on investments.

The stock dropped 4.03% in pre-market trading to $9.52, well below its 52-week high of $23.65, reflecting investor concerns.

Management cited challenging market conditions, with CLO equity effective yield falling 210 bps and cash distribution yield dropping 230 bps.

Oxford Lane aims to stabilize NAV and investment income in coming quarters.

More News
Today / 14:40
|
851

Vallourec Q1 2026 Beats Forecasts, Stock Fluctuates

Vallourec Q1 2026 earnings beat forecasts; stock sees volatility. Strong EBITDA and cash flow highlight performance.

0
Today / 14:20
|
888

Home Depot Q1 2026 earnings beat forecasts, stock dips

Home Depot Q1 2026 earnings beat forecasts with EPS of $3.43 and revenue of $41.8B. Stock dips 2.49% amid margin concerns.

0
Today / 14:03
|
352

Hera Group Q1 2026: Steady growth

Hera Group posts steady growth in Q1 2026 with net profit of EUR 155 million and EPS of $0.105.

0
Today / 13:43
|
246

Driven Brands Q4 2025 Revenue Growth Reported

Driven Brands Q4 2025 revenue grows 7.7% to $460.1M, EPS $0.34. Stock up 1.12%.

0
Today / 13:41
|
777

Ceragon Q1 2026 Revenue Beats Estimates

Ceragon Networks Q1 2026 revenue beat estimates at $85M. EPS $0.01. Stock rose 6.77% premarket. Full-year guidance reiterated.

0
Today / 13:10
|
739

Fractyl Health Q1 2026 EPS Beat, Shares Surge 23%

Fractyl Health Q1 2026 EPS beat expectations by 76%, shares surged 23% after hours. Revita program data expected in Q4 2026.

0
Today / 13:01
|
272

Antalpha Q1 2026: EPS Misses Forecast, Stock Rises

Antalpha Q1 2026: EPS misses forecast at $0.07, stock rises 2.42%. Revenue up 52% to $20.7M. Web3 AI agent Nina launched. Q2 guidance $11M-$13M.

0
Today / 12:44
|
314

GNFC Q4 profit surges, stock climbs 5.17%

GNFC Q4 FY2026 strong results: revenue up 11%, PAT up 35%, stock rises 5.17%. Chemical segment drives growth.

0
Today / 12:42
|
677

Relmada TX Q1 2026: Loss and stock dip

Relmada Therapeutics Q1 2026 results: stock declines, strong cash position and NDV-01 program in focus.

0
Today / 12:00
|
958

Inovio Beats Q1 2026 EPS Forecast, Stock Slips

Inovio Q1 2026 EPS beats forecasts, but stock falls. Detailed financial analysis and outlook on Bond.az.

0
Today / 11:50
|
449

CytoSorbents Q1 2026 Misses Forecasts, Stock Falls

CytoSorbents Q1 2026 results: EPS of -$0.05 misses estimate, revenue of $8.9M falls short, stock drops 7.53%. Company cuts costs and targets breakeven in H2 2026.

0
Today / 10:53
|
859

IOC Q4 2026 earnings beat expectations

IOC Q4 2026 earnings beat expectations with EPS of 6.15, a 20.59% surprise. Stock rose 2.42%. Record refining throughput and 184% profit growth reported.

0
...